Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|88|5|281-288

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.5, 2015-01, pp. : 281-288

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 36-42

Karger

Access to resources Recommend Favorite

Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes

By  

Oncology, Vol. 93, Iss. 2, 2017-05 ,pp. : 127-135

Karger

Access to resources Recommend Favorite

Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 337-342

Karger

Access to resources Recommend Favorite

Complete Response of Highly Advanced Gastric Cancer with Peritoneal Dissemination after New Combined Chemotherapy of S-1 and Low-Dose Cisplatin: Report of a Case

By  

Oncology, Vol. 61, Iss. 1, 2001-07 ,pp. : 16-22

Karger

Access to resources Recommend Favorite

A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S‐1 plus intravenous paclitaxel for serosa‐positive gastric cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 8, 2015-06 ,pp. : 1041-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite